• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Design Therapeutics Inc.

    2/7/25 4:15:38 PM ET
    $DSGN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $DSGN alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 1)


    DESIGN THERAPEUTICS, INC.

    (Name of Issuer)


    Common Stock

    (Title of Class of Securities)


    25056L103

    (CUSIP Number)


    12/31/2024

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    25056L103


    1Names of Reporting Persons

    Light Irrevocable Trust #1 dated April 22, 2019
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    NEVADA
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    3,834,355.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    3,834,355.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    3,834,355.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    6.9 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    25056L103


    1Names of Reporting Persons

    Jason Howerton
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    0.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    0.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    0.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.0 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    DESIGN THERAPEUTICS, INC.
    (b)Address of issuer's principal executive offices:

    6005 HIDDEN VALLEY ROAD, SUITE 110, CARLSBAD, CA, 92011.
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the 'Reporting Persons') are: Light Irrevocable Trust #1 dated April 22, 2019 Jason Howerton
    (b)Address or principal business office or, if none, residence:

    Light Irrevocable Trust #1 dated April 22, 2019 241 Ridge Street, Suite 100 Reno, NV 89501 Jason Howerton 2114 Via Tiempo Cardiff, CA 92007
    (c)Citizenship:

    Light Irrevocable Trust #1 dated April 22, 2019 - Nevada Jason Howerton - United States
    (d)Title of class of securities:

    Common Stock
    (e)CUSIP No.:

    25056L103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    Row 9 of each Reporting Person's cover page to this Schedule 13G sets forth the aggregate number of shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. Jason Howerton was the sole trustee of Light Trust Irrevocable Trust #1 ("Light Trust") until October 1, 2024.
    (b)Percent of class:

    Row 11 of each Reporting Person's cover page to this Schedule 13G sets forth the percentage of the shares of Common Stock beneficially owned by such Reporting Person and is incorporated by reference. The percentage set forth in each row 11 is calculated based on 56,621,037 shares of Common Stock outstanding as of November 4, 2024, as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on November 7, 2024.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

     (ii) Shared power to vote or to direct the vote:

    Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of Common Stock beneficially owned by such Reporting Person and is incorporated by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    Not Applicable

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Light Irrevocable Trust #1 dated April 22, 2019
     
    Signature:/s/ Daniel D. Sands
    Name/Title:By Dunham Trust Company, LLC, its Trustee, By Daniel D. Sands, Director of Trust Investments
    Date:02/07/2025
     
    Jason Howerton
     
    Signature:/s/ Jason Howerton
    Name/Title:Jason Howerton
    Date:02/07/2025
    Get the next $DSGN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $DSGN

    DatePrice TargetRatingAnalyst
    5/7/2024$6.00 → $12.00Neutral → Overweight
    Piper Sandler
    11/14/2023$42.00 → $6.00Overweight → Neutral
    Piper Sandler
    8/15/2023$19.00 → $6.00Outperform → Neutral
    Wedbush
    8/15/2023$23.00 → $7.00Outperform → Sector Perform
    RBC Capital Mkts
    8/15/2023$6.00Outperform → Market Perform
    SVB Securities
    5/4/2023$6.00Sell → Neutral
    Goldman
    6/10/2022$21.00Outperform
    Wedbush
    5/2/2022$30.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $DSGN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Design Therapeutics Highlights Momentum Across Lead GeneTAC® Programs and Reports First Quarter 2025 Financial Results

      Phase 1 Single Ascending Dose Trial of DT-216P2 for Friedreich Ataxia (FA) Program Ongoing Reported Favorable Phase 1 Data for DT-168 for Fuchs Endothelial Corneal Dystrophy (FECD) Program Well-Capitalized with Cash and Securities of $229.7 Million to Fund Operations Through up to Four Potential Clinical Proof-of-Concept Data Sets CARLSBAD, Calif., May 07, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced progress across its portfolio of GeneTAC® candidates and reported financial results for the first quarter 2025. "Design continued its progress throug

      5/7/25 4:01:00 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Design Therapeutics Announces Favorable Phase 1 Data for DT-168 Supporting Advancement into Phase 2 Biomarker Trial for Patients with Fuchs Endothelial Corneal Dystrophy

      CARLSBAD, Calif., May 01, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced favorable data from a Phase 1 single- and multiple-ascending dose (SAD/MAD) trial of DT-168 in healthy volunteers, which will be presented on May 2, 2025 at Eyecelerator @ Park City 2025, an event backed by the American Academy of Ophthalmology highlighting industry advancements and innovative new products disrupting eye care. DT-168 is a novel GeneTAC® small molecule, formulated as an eye drop, that is designed to selectively target and reduce the expression of the mutant TCF4 ge

      5/1/25 8:00:00 AM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Design Therapeutics to Present Phase 1 Data for Fuchs Endothelial Corneal Dystrophy Program at Eyecelerator @ Park City 2025

      CARLSBAD, Calif., April 21, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that it will present an update on the progress of its DT-168 program for Fuchs endothelial corneal dystrophy (FECD) at Eyecelerator @ Park City 2025 on Friday, May 2, 2025, at 1:30 p.m. MT in Park City, UT. The presentation will include safety findings from the Phase 1 single- and multiple-ascending dose trial of DT-168 in healthy adult volunteers and plans for Phase 2 clinical development in FECD patients. DT-168 is a GeneTAC® small molecule, formulated as an eye drop, that is

      4/21/25 4:01:00 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DSGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 3 filed by new insider Dunham Trust Co

      3 - Design Therapeutics, Inc. (0001807120) (Issuer)

      2/7/25 4:17:28 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by Director Lappe Rodney W

      4 - Design Therapeutics, Inc. (0001807120) (Issuer)

      1/6/25 7:00:35 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 4 filed by President, CEO and Chairperson Shah Pratik

      4 - Design Therapeutics, Inc. (0001807120) (Issuer)

      1/6/25 7:00:31 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DSGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more

    $DSGN
    SEC Filings

    See more

    $DSGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more

    $DSGN
    Financials

    Live finance-specific insights

    See more

    $DSGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Amendment: SEC Form SC 13D/A filed by Design Therapeutics Inc.

      SC 13D/A - Design Therapeutics, Inc. (0001807120) (Subject)

      8/13/24 6:53:06 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Design Therapeutics Inc. (Amendment)

      SC 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)

      2/14/24 4:58:16 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Design Therapeutics Inc. (Amendment)

      SC 13G/A - Design Therapeutics, Inc. (0001807120) (Subject)

      2/14/24 3:01:26 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form S-3 filed by Design Therapeutics Inc.

      S-3 - Design Therapeutics, Inc. (0001807120) (Filer)

      5/7/25 4:54:16 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form 10-Q filed by Design Therapeutics Inc.

      10-Q - Design Therapeutics, Inc. (0001807120) (Filer)

      5/7/25 4:07:23 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Design Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Design Therapeutics, Inc. (0001807120) (Filer)

      5/7/25 4:04:40 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Design Therapeutics upgraded by Piper Sandler with a new price target

      Piper Sandler upgraded Design Therapeutics from Neutral to Overweight and set a new price target of $12.00 from $6.00 previously

      5/7/24 6:22:26 AM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Design Therapeutics downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Design Therapeutics from Overweight to Neutral and set a new price target of $6.00 from $42.00 previously

      11/14/23 11:39:53 AM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Design Therapeutics downgraded by Wedbush with a new price target

      Wedbush downgraded Design Therapeutics from Outperform to Neutral and set a new price target of $6.00 from $19.00 previously

      8/15/23 7:30:45 AM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Design Therapeutics Outlines Progress Across GeneTAC™ Platform and Announces Fourth Quarter and Full Year 2023 Financial Results

      New Drug Product for Friedreich Ataxia (FA) DT-216P2 with Favorable Nonclinical Pharmacokinetic and Injection Site Safety Profile; Complete GLP Studies by Year-end 2024 to Start Patient Trials in 2025 IND Cleared for DT-168 for Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) with Phase 1 Development to Start in 2024; Observational Study Underway to Confirm Patient Characteristics and Evaluate Potential Endpoints New Program Unveiled for Huntington's Disease (HD) Targeting Reduction of Mutant Huntingtin with a GeneTAC™ Small Molecule Cash and Securities of $281.8 Million at Year-end 2023 Support Five-Year Operating Runway and Advancement of Up to Four Progra

      3/19/24 4:01:00 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Design Therapeutics to Webcast Fourth Quarter and Full Year 2023 Financial Results and Comprehensive Portfolio Update

      CARLSBAD, Calif., March 12, 2024 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for serious degenerative genetic diseases, today announced that the company will host a conference call and live webcast on Tuesday, March 19, 2024, at 4:30 p.m. ET to discuss its fourth quarter and full year 2023 financial results and provide a comprehensive portfolio update. The event will be webcast live under the "Events" section of the Investors page of www.designtx.com and can also be accessed here. A replay of the webcast will be archived on the Design website for 30 days. Dial-in information for conference participants may be obtained by regi

      3/12/24 6:30:00 AM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Design Therapeutics Reports Initial Results from Phase 1 Multiple-Ascending Dose Study of DT-216 for the Treatment of Friedrich Ataxia

      DT-216 Resulted in a Significant Increase in FXN mRNA Levels in Skeletal Muscle of FA Patients Treatment Generally Well-Tolerated; Injection Site Reactions Attributable to Current Formulation Composition Design Plans to Proceed with an Improved DT-216 Formulation and Initiate a Multiple Dose Phase 1 Clinical Study in the Second Half of 2024 Conference Call and Webcast to be Held Today at 4:30pm ET CARLSBAD, Calif., Aug. 14, 2023 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today reported initial results from the company's Phase 1 multiple-ascending dose (MAD) clinical

      8/14/23 4:01:00 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Schmid John P. bought $99,738 worth of shares (26,965 units at $3.70) (SEC Form 4)

      4 - Design Therapeutics, Inc. (0001807120) (Issuer)

      3/25/24 7:10:26 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Berger Heather A. bought $4,866 worth of shares (1,300 units at $3.74) (SEC Form 4)

      4 - Design Therapeutics, Inc. (0001807120) (Issuer)

      3/25/24 7:09:14 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Lappe Rodney W bought $49,287 worth of shares (21,000 units at $2.35), increasing direct ownership by 19% to 133,024 units (SEC Form 4)

      4 - Design Therapeutics, Inc. (0001807120) (Issuer)

      10/2/23 6:01:58 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $DSGN
    Leadership Updates

    Live Leadership Updates

    See more
    • Design Therapeutics Appoints Veteran Industry Executive Chris Storgard, M.D., as Chief Medical Officer

      CARLSBAD, Calif., April 17, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced the appointment of Chris M. Storgard, M.D., as Chief Medical Officer (CMO). Dr. Storgard brings over two decades of leadership and hands-on drug development experience, having successfully advanced multiple assets from preclinical stages through global regulatory approvals. "We are thrilled to welcome Chris to our team at this exciting time for Design, as we advance our portfolio of GeneTAC® small molecules toward key clinical milestones," said Pratik Shah, Ph.D., chairperson an

      4/17/25 8:00:00 AM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bright Peak Therapeutics Appoints John Schmid to its Board of Directors

      SAN DIEGO and BASEL, Switzerland , April 17, 2025 (GLOBE NEWSWIRE) -- Bright Peak Therapeutics, a clinical-stage biotechnology company focused on discovering and developing multifunctional immunotherapies for cancer, today announced the appointment of John Schmid, a seasoned biotechnology executive, to its Board of Directors. "It is a pleasure to welcome John to our Board," said Fredrik Wiklund, Chief Executive Officer of Bright Peak Therapeutics. "John brings decades of experience and an extensive track record of success in the biotech sector. His strategic insights and financial expertise will be instrumental as we advance our clinical pipeline and scale Bright Peak for long-term succ

      4/17/25 7:00:00 AM ET
      $ANAB
      $DSGN
      $PSTX
      $XERS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Business Services
    • Design Therapeutics Reports Pipeline and Business Progress and Fourth Quarter and Full Year 2021 Financial Results

      Phase 1 Trial of DT-216, a Novel FA GeneTAC™ Molecule, in Patients with Friedreich Ataxia On Track to Begin Soon Preclinical Data Supporting Development of Novel GeneTAC™ Small Molecules for the Treatment of Fuchs Endothelial Corneal Dystrophy (FECD) to be Presented at ARVO 2022 Well-Capitalized with $384.1 Million in Cash and Investments at the End of 2021 to Support Upcoming Milestones CARLSBAD, Calif., March 10, 2022 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (NASDAQ:DSGN), a biotechnology company developing treatments for degenerative genetic disorders, today announced pipeline and business progress and reported fourth quarter and full year 2021 financial results. "This is an e

      3/10/22 4:02:00 PM ET
      $DSGN
      Biotechnology: Pharmaceutical Preparations
      Health Care